Schneeweiss Andreas, Hartkopf Andreas D, Müller Volkmar, Wöckel Achim, Lux Michael P, Janni Wolfgang, Ettl Johannes, Belleville Erik, Huober Jens, Thill Marc, Fasching Peter A, Kolberg Hans-Christian, Pöschke Patrik, Welslau Manfred, Overkamp Friedrich, Tesch Hans, Fehm Tanja N, Lüftner Diana, Schütz Florian
National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital and German Cancer Research Center, Heidelberg, Germany.
Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Geburtshilfe Frauenheilkd. 2020 Mar;80(3):277-287. doi: 10.1055/a-1111-2431. Epub 2020 Mar 4.
This review is intended to present the latest developments in the prevention and treatment of early breast cancer. The risk of breast cancer can be increasingly better characterised with large epidemiological studies on genetic and non-genetic risk factors. Through new analyses, the evidence for high-penetrance genes as well as for low-penetrance genes was able to be improved. New data on denosumab and atezolizumab are available in the neoadjuvant situation as is a pooled appraisal of numerous studies on capecitabine in the curative situation. There is also an update to the overall survival data of pertuzumab in the adjuvant situation with a longer follow-up observation period. Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.
本综述旨在介绍早期乳腺癌预防和治疗的最新进展。通过对遗传和非遗传风险因素进行大规模流行病学研究,乳腺癌风险能够得到越来越精确的描述。通过新的分析,高 penetrance 基因以及低 penetrance 基因的证据得以完善。在新辅助治疗方面有地诺单抗和阿特珠单抗的新数据,在根治性治疗方面有对众多关于卡培他滨研究的汇总评估。在辅助治疗中,随着随访观察期延长,帕妥珠单抗的总生存数据也有更新。最后,数字医学正稳步进入科学领域。最近一项关于使用人工智能进行乳腺癌自动检测的研究为未来临床研究综述奠定了基础。 (注:“penetrance”在医学领域可能有特定专业含义,这里直接保留英文未翻译,可根据具体医学背景准确翻译,比如“外显率”等 )